BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

140 related articles for article (PubMed ID: 661315)

  • 1. A radioimmunoassay for serum medroxyprogesterone acetate.
    Shrimanker K; Saxena BN; Fotherby K
    J Steroid Biochem; 1978 Apr; 9(4):359-63. PubMed ID: 661315
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Radioimmunoassay for medroxyprogesterone acetate (Provera) using the 11alpha-hydroxy succinyl conjugate.
    Royer ME; Ko H; Campbell JA; Murray HC; Evans JS; Kaiser DG
    Steroids; 1974 May; 23(5):713-30. PubMed ID: 4365969
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radioimmunoassay of serum medroxyprogesterone acetate (Provera) in women following oral and intravaginal administration.
    Hiroi M; Stanczyk FZ; Goebelsmann U; Brenner PF; Lumkin ME; Mishell DR
    Steroids; 1975 Sep; 26(3):373-86. PubMed ID: 1198624
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radioimmunoassay for serum medroxyprogesterone acetate in Thai women receiving injectable DMPA contraceptive.
    Werawatgoompa S; Pongpradit T; Leepipatpaiboon S; Sukanthanak A
    Contraception; 1979 Oct; 20(4):319-27. PubMed ID: 509958
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetic study of different doses of Depo Provera.
    Fotherby K; Koetsawang S; Mathrubutham M
    Contraception; 1980 Nov; 22(5):527-36. PubMed ID: 6451351
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Medroxyprogesterone acetate in human serum.
    Mathrubutham M; Fotherby K
    J Steroid Biochem; 1981 Aug; 14(8):783-6. PubMed ID: 6457936
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Serum medroxyprogesterone acetate (MPA) concentrations and ovarian function following intramuscular injection of depo-MPA.
    Ortiz A; Hirol M; Stanczyk FZ; Goebelsmann U; Mishell DR
    J Clin Endocrinol Metab; 1977 Jan; 44(1):32-8. PubMed ID: 833262
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Plasma levels of medroxyprogesterone acetate (MPA), estradiol and progesterone in the rhesus monkey after intramuscular adminstration of Depo-Provera.
    Mora G; Johansson ED
    Contraception; 1976 Sep; 14(3):343-50. PubMed ID: 824097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Plasma levels of medroxyprogesterone acetate (MPA), sex-hormone binding globulin, gonadal steroids, gonadotrophins and prolactin in women during long-term use of depo-MPA (Depo-Provera) as a contraceptive agent.
    Jeppsson S; Gershagen S; Johansson ED; Rannevik G
    Acta Endocrinol (Copenh); 1982 Mar; 99(3):339-43. PubMed ID: 6461995
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Timing of onset of contraceptive effectiveness in Depo-Provera users: Part I. Changes in cervical mucus.
    Petta CA; Faundes A; Dunson TR; Ramos M; DeLucio M; Faundes D; Bahamondes L
    Fertil Steril; 1998 Feb; 69(2):252-7. PubMed ID: 9496338
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Forearm bone density in users of Depo-Provera as a contraceptive method.
    Bahamondes L; Perrotti M; Castro S; Faúndes D; Petta C; Bedone A
    Fertil Steril; 1999 May; 71(5):849-52. PubMed ID: 10231044
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Plasma medroxyprogesterone acetate levels following intramuscular or oral administration in patients with endometrial adenocarcinoma.
    Laatikainen T; Nieminen U; Adlercreutz H
    Acta Obstet Gynecol Scand; 1979; 58(1):95-9. PubMed ID: 419965
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A preliminary pharmacokinetic and pharmacodynamic evaluation of depot-medroxyprogesterone acetate and norethisterone oenanthate.
    Fotherby K; Saxena BN; Shrimanker K; Hingorani V; Takker D; Diczfalusy E; Landgren BM
    Fertil Steril; 1980 Aug; 34(2):131-9. PubMed ID: 7409232
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A case for concern?
    Gartland A
    Nurs Times; 1983 May 4-10; 79(18):10-1. PubMed ID: 6222288
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Endometrial histology and circulating levels of medroxyprogesterone acetate (MPA), estradiol, FSH and LH in women with MPA induced amenorrhoea compared with women with secondary amenorrhoea.
    Jeppsson S; Johansson ED; Ljungberg O; Sjöberg NO
    Acta Obstet Gynecol Scand; 1977; 56(1):43-8. PubMed ID: 842303
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of breast cancer with medroxyprogesterone acetate.
    Muggia FM; Cassieth PA; Ochoa M; Flatow FA; Gellhorn A; Hyman GA
    Ann Intern Med; 1968 Feb; 68(2):328-37. PubMed ID: 4306126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of medroxyprogesterone serum concentrations by the oral or intramuscular route in patients with persistent or recurrent endometrial carcinoma.
    Sall S; DiSaia P; Morrow CP; Mortel R; Prem K; Thigpen T; Creasman W
    Am J Obstet Gynecol; 1979 Nov; 135(5):647-50. PubMed ID: 507117
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The effect of medroxyprogesterone acetate on gonadotropin secretion in girls with precocious puberty.
    Warren MP; Mathews JH; Morishima A; Vande Wiele R
    Am J Med Sci; 1975; 269(3):375-81. PubMed ID: 1155493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Timing of onset of contraceptive effectiveness in Depo-Provera users. II. Effects on ovarian function.
    Petta CA; Faúndes A; Dunson TR; Ramos M; DeLucio M; Faúndes D; Bahamondes L
    Fertil Steril; 1998 Nov; 70(5):817-20. PubMed ID: 9806559
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Treatment of seizures with medroxyprogesterone acetate: preliminary report.
    Mattson RH; Cramer JA; Caldwell BV; Siconolfi BC
    Neurology; 1984 Sep; 34(9):1255-8. PubMed ID: 6540415
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.